IMMIX BIOPHARMA, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
IMMIX BIOPHARMA, INC. (IMMX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.13 million as of 2025-12-31, per its 10-K/A filed 2026-03-27.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-27
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.13M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $775.25K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $109.86K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $149.60K; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $1.17M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $1.13M 10-K/A · filed 2026-03-27 | |
| 2024-12-31 | $775.25K 10-K/A · filed 2026-03-27 | |
| 2023-12-31 | $109.86K 10-K · filed 2025-03-25 | |
| 2022-12-31 | $149.60K 10-K · filed 2024-03-29 | $1.17M 10-K · filed 2023-03-27 |
| 2021-12-31 | $105.75K 10-K · filed 2023-03-27 | |
| 2020-12-31 | $43.64K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |